Last reviewed · How we verify
An 8-week Open-Label Flexible-Dose Study Of Desvenlafaxine as Monotherapy In The Treatment Of Dysthymia
This multi-centred study will be conducted at two centres. The design will be an open label, flexible-dose study. This investigation will evaluate the efficacy of Desvenlafaxine monotherapy for patients who meet diagnostic criteria for dysthymia.
Details
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | 2012-08 |
| Completion | 2014-06 |
Conditions
- Dysthymic Disorder
Interventions
- Desvenlafaxine
Primary outcomes
- Montgomery-Åsberg Depression Rating Scale — 8 Weeks
Countries
Canada